Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

Janzic, Urska; Shalata, Walid; Szymczak, Katarzyna; Dziadziuszko, Rafał; Jakopovic, Marko; Mountzios, Giannis; Płużański, Adam; A, Araujo; Charpidou, Andriani; Agbarya, Abed

Publication

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations

2023-08Journal article

dc.contributor.author	Janzic, Urska
dc.contributor.author	Shalata, Walid
dc.contributor.author	Szymczak, Katarzyna
dc.contributor.author	Dziadziuszko, Rafał
dc.contributor.author	Jakopovic, Marko
dc.contributor.author	Mountzios, Giannis
dc.contributor.author	Płużański, Adam
dc.contributor.author	A, Araujo
dc.contributor.author	Charpidou, Andriani
dc.contributor.author	Agbarya, Abed
dc.date.accessioned	2024-07-23T10:34:05Z
dc.date.available	2024-07-23T10:34:05Z
dc.date.issued	2023-08
dc.description.abstract	BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	Janzic U, Shalata W, Szymczak K, et al. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. Int J Mol Sci. 2023;24(16):12840. doi:10.3390/ijms241612840	pt_PT
dc.identifier.doi	10.3390/ijms241612840	pt_PT
dc.identifier.issn	1422-0067
dc.identifier.uri	http://hdl.handle.net/10400.16/3018
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.publisher	MDPI	pt_PT
dc.relation.publisherversion	https://doi.org/10.3390/ijms241612840	pt_PT
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	pt_PT
dc.subject	BRAF V600E mutation	pt_PT
dc.subject	cMET exon 14 skipping mutation	pt_PT
dc.subject	first-line treatment	pt_PT
dc.subject	non-small-cell lung cancer	pt_PT
dc.subject	real-world data	pt_PT
dc.subject	targeted therapy	pt_PT
dc.title	Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations	pt_PT
dc.type	journal article
dspace.entity.type	Publication
oaire.citation.conferencePlace	Switzerland	pt_PT
oaire.citation.issue	16	pt_PT
oaire.citation.startPage	12840	pt_PT
oaire.citation.title	International Journal of Molecular Sciences	pt_PT
oaire.citation.volume	24	pt_PT
person.familyName	Araújo
person.givenName	António
person.identifier.ciencia-id	0715-EC47-869F
person.identifier.orcid	0000-0002-7267-3584
person.identifier.rid	B-5047-2008
person.identifier.scopus-author-id	16229446200
rcaap.rights	openAccess	pt_PT
rcaap.type	article	pt_PT
relation.isAuthorOfPublication	782f6844-6bc9-48e9-9967-47d0a20be2c3
relation.isAuthorOfPublication.latestForDiscovery	782f6844-6bc9-48e9-9967-47d0a20be2c3